Biomarker Endpoints in EBC-46 Clinical Research: What Researchers Are Measuring and Why
The biomarkers chosen for EBC-46 trials are not arbitrary — they reflect the current scientific understanding of how tigilanol tiglate kills tumours. Here's what researchers are measuring and why it matters.
Why Biomarker Selection Reveals Scientific Confidence
In early-phase oncology trials, the choice of biomarker endpoints tells you something important: it reveals what the trial designers believe about the drug's mechanism. A trial measuring vascular response biomarkers is a trial where researchers are confident that vascular disruption is a primary mechanism. A trial measuring immune activation markers is a trial where the immune cascade is considered central.[1]
EBC-46's biomarker profile in current trials reflects a mechanistic understanding built on both veterinary data and the existing body of PKC biology research. The endpoints being used are not exploratory guesses — they are grounded in a decade of preclinical work and real-world Stelfonta outcomes in canine oncology.
Tumour Response as the Primary Endpoint
The most fundamental endpoint in EBC-46 trials is objective tumour response — the measurable reduction in tumour size as assessed by imaging and physical examination. In the Phase I trial data published by Panizza et al. (2019), covering head and neck squamous cell carcinoma patients, objective response rate was the primary efficacy endpoint.[2]
Responses in that data set were defined using standard RECIST criteria — classifying outcomes as complete response, partial response, stable disease, or progressive disease. The results showed a significant proportion of patients achieving objective responses, justifying progression to Phase II investigation.
Vascular and Necrosis Biomarkers
Because EBC-46's mechanism involves vascular disruption — the collapse of blood vessels supplying the tumour — vascular biology biomarkers are central to the mechanistic endpoint package. These include circulating endothelial cells (CECs), vascular endothelial growth factor (VEGF) levels, and dynamic contrast-enhanced MRI measurements of tumour perfusion.[3]
Post-treatment biopsy samples are assessed for necrosis extent — the area of dead tumour tissue as a percentage of total tumour volume. In preclinical studies, tigilanol tiglate produced rapid and extensive necrosis within 24 hours of intratumoral injection. Confirming this pattern in human tissue biopsies is an important validation step for the mechanism.
Immune Activation Markers
The downstream immune response to PKC activation is increasingly recognised as central to EBC-46's mechanism — not merely a secondary effect of tumour necrosis. As tumour cells die and release damage-associated molecular patterns (DAMPs), they trigger dendritic cell activation and T-cell recruitment.[4]
Trials are therefore measuring markers of this immune cascade: tumour-infiltrating lymphocyte (TIL) density in biopsy samples, circulating CD8+ T-cell levels, and cytokine profiles including IL-6, TNF-α, and interferon-γ. The hypothesis is that EBC-46 does not merely kill the injected tumour but may prime a systemic immune response that helps address distant or microscopic disease.
This is the "abscopal effect" hypothesis being tested: that local intratumoral treatment could generate systemic anti-tumour immunity. If confirmed in human trials, it would substantially expand the potential clinical utility of the compound beyond locally injectable tumours.
Safety Biomarkers and Phase I Priorities
Phase I trials are fundamentally safety studies, and the biomarker panel includes standard hepatic, renal, and haematological safety markers. Given tigilanol tiglate's intratumoral delivery route and the fact that preclinical and veterinary data showed minimal systemic distribution, the expectation is a clean safety profile.[5]
Local injection site reactions — erythema, oedema, transient pain — are anticipated and documented, as they reflect the intended local vascular and inflammatory response. Distinguishing expected on-mechanism local effects from unexpected systemic adverse events is a key safety evaluation task in Phase I.
What the Endpoints Tell Us About the Future
The breadth of biomarker endpoints in EBC-46 trials reflects a compound being evaluated not just for local tumour ablation but for its potential role in a broader immunological strategy. The researchers are asking not only "does it kill this tumour?" but "does killing this tumour with EBC-46 do something useful to the immune system?"[6]
The answer to that second question could define the compound's long-term clinical positioning — either as a standalone local ablation tool or as a component of combination strategies with checkpoint inhibitors or other immunotherapies. The biomarkers being collected today are the data that will answer it.
References
- 1. ClinicalTrials.gov — tigilanol tiglate registered studies. View source ↗
- 2, 5. Panizza BJ et al. "Phase I dose-escalation study of intratumoural tigilanol tiglate." EJC. 2019. View source ↗
- 3. Boyle GM et al. "Intratumoural injection of EBC-46 rapidly ablates tumours." PLOS ONE. 2014. View source ↗
- 4. Newton AC. "Protein kinase C: perfectly balanced." Crit Rev Biochem Mol Biol. 2018. View source ↗
- 6. QIMR Berghofer — EBC-46 research programme. View source ↗
